个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Han Weiming[1] * ; Wang Lan[2] * ; Li Chen[3] ; Chen Junqiang[4] ; Zhang Wencheng[3] ; Wang Xin[1] ; Pang Qingsong[3] ; Zhao Yidian[5] ; Sun Xinchen[6] ; Zhang Kaixian[7] ; Li Gaofeng[8] ; Li Ling[7] ; Qiao Xueying[2] ; Liu Miaoling[9] ; Wang Yadi[10] ; Deng Lei[1] ; Wang Wenqing[1] ; Bi Nan[1] ; Zhang Tao[1] ; Deng Wei[11] ; Ni Wenjie[12] ; Chang Xiao[1] ; Zhou Zongmei[1] ; Liang Jun[13] ; Feng Qinfu[1] ; Wang Lvhua[13] ; Chen Dongfu[1] ; Lv Jima[1] ; Zhu Shuchai[2] ; Han Chun[2,*2] ; Xiao Zefen[1,*1] ;
机构： [1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [2]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [3]Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin, China. [4]Department of Radiation Oncology, Fujian Cancer Hospital/Fujian Medical University Cancer Hospital, Fuzhou, China. [5]Department of Radiation Oncology, Anyang Cancer Hospital, Anyang, China. [6]Department of Radiation Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [7]Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, China. [8]Department of Radiation Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China. [9]Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China. [10]Department of Radiation Oncology, PLA Army General Hospital, Beijing, China. [11]Department of Radiation Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Beijing Institute for Cancer Research, Beijing, P.R. China. [12]Department of Radiation Oncology, Beijing Shijitan Hospital, Capital Medical University, Ninth School of Clinical Medicine, Peking University, School of Oncology, Capital Medical University, Beijing, P.R. China. [13]Department of Radiation Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital, Shenzhen, China
出处：
DOI： 10.1177/17588359221131526
ISSN：

关键词： esophageal cancer overall survival progression-free survival radiotherapy surrogate endpoint

摘要：
The surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal squamous cell carcinoma (ESCC) remains unelucidated. This study aimed to determine the validity of PFS as a surrogate endpoint for OS in ESCC patients treated with definitive radiotherapy or definitive chemoradiotherapy (dRT/dCRT), as well as characterize the prognostic factors and survival of such patients.A total of 3662 patients from 10 cancer centers were enrolled. One-, 2-, and 3-year PFS (PFS12, PFS24, and PSF36, respectively) were used as time points for analysis. At each time point, ESCC-specific mortality and OS were characterized using competing risk and conditional survival models, while correlation between PFS and OS was evaluated by linear regression.At PFS12, PFS24, and PFS36, a progressive decrease in 5-year ESCC-specific mortality (35.2%-13.4%) and increase in 5-year OS (46.6%-62.9%) were observed. Regardless, the OS of patients remained markedly lower than those of the age- and sex-matched Chinese general population. TNM stage remained a significant prognostic factor at PFS36. Strong correlation was found between 3-year PFS and 5-year OS, which was further externally validated.Three-year PFS may act as a potential surrogate endpoint for 5-year OS. TNM stage was considered a significant prognostic factor for OS, and may represent the optimal prognostic tool to guide clinical decision-making and post-treatment follow-up.© The Author(s), 2022.

基金：
Beijing Hope Run Special Fund of the Cancer Foundation of China (LC2016L04).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [2]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [*1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan South Lane, Chaoyang District, Beijing, 100021, China [*2]Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, No.12, Health Road, Shijiazhuang, Hebei, China.
推荐引用方式(GB/T 7714)：
Han Weiming,Wang Lan,Li Chen,et al.Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis[J].THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.2022,14:17588359221131526.doi:10.1177/17588359221131526.
APA：
Han Weiming,Wang Lan,Li Chen,Chen Junqiang,Zhang Wencheng...&Xiao Zefen.(2022).Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis.THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY,14,
MLA：
Han Weiming,et al."Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis".THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 14.(2022):17588359221131526

相关文献

[1]Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment [2]骨髓增生异常综合征患者淋巴细胞绝对值计数与地西他滨治疗反应的关系 [3]Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02 [4]Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01 [5]The benefit of radiotherapy in distant metastatic small-cell lung cancer: A retrospective study based on propensity score matching (PSM) [6]Dose escalation of 3D radiotherapy is effective for esophageal squamous cell carcinoma: a multicenter retrospective analysis (3JECROG R-03) [7]The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen. [8]Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01 [9]Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma [10]Interobserver variability in target volume delineation in definitive radiotherapy for thoracic esophageal cancer: a multi-center study from China

资源点击量：15100 今日访问量：0 总访问量：960 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号